Forte Biosciences (FBRX) Times Interest Earned (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Times Interest Earned of -$0.51 for Q1 2026, up 97.38% year-over-year from -$0.26 in Q1 2025, and up 99.91% quarter-over-quarter from -$571.42 in Q4 2025.
Forte Biosciences (FBRX) Times Interest Earned (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Times Interest Earned for 11 consecutive years, with -$0.51 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 97.38% year-over-year to -$0.51; the TTM figure through Mar 2026 stood at -$1.76 (up 96.77% YoY), while the FY2025 annual figure was -$1.5, changed 0.48% from the prior year.
- Times Interest Earned improved to -$0.51 in Q1 2026 per FBRX's latest filing, from -$571.42 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.51 in Q1 2026 and bottomed at -$2043.2 in Q3 2023.
- Historically, Times Interest Earned has averaged -$253.17 across 5 years, with a median of -$90.75 in 2024.
- Annual changes were most pronounced in 2023 — Times Interest Earned plunged 5749.65% — and 2025, when it jumped 99.8%.
- Forte Biosciences' Times Interest Earned stood at -$75.98 in 2022, then sank by 179.93% to -$212.7 in 2023, then soared by 57.33% to -$90.75 in 2024, then plunged by 529.64% to -$571.42 in 2025, then jumped by 99.91% to -$0.51 in 2026.
- Business Quant data shows FBRX's Times Interest Earned at -$0.51 in Q1 2026, -$571.42 in Q4 2025, and -$1.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -0.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.72 |
| Mar 31, 2026 | -0.51 |
| Dec 31, 2025 | -571.42 |
| Sep 30, 2025 | -1.06 |
| Jun 30, 2025 | -0.89 |
| Mar 31, 2025 | -19.62 |
| Dec 31, 2024 | -90.75 |
| Sep 30, 2024 | -308.18 |
| Jun 30, 2024 | -442.00 |
| Mar 31, 2024 | -278.71 |
| Dec 31, 2023 | -212.70 |
| Sep 30, 2023 | -2,043.20 |
| Jun 30, 2023 | -103.84 |
| Mar 31, 2023 | -97.93 |
| Dec 31, 2022 | -75.98 |
| Sep 30, 2022 | -34.93 |
| Jun 30, 2022 | -13.85 |
| Mar 31, 2022 | -8.27 |
| Dec 31, 2021 | -5.35 |
| Sep 30, 2021 | -7.43 |